<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lynn RC</submitter><funding>Howard Hughes Medical Institute</funding><funding>NHGRI NIH HHS</funding><funding>NIH HHS</funding><pagination>293-300</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6944329</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>576(7786)</volume><pubmed_abstract>Chimeric antigen receptor (CAR) T cells mediate anti-tumour effects in a small subset of patients with cancer&lt;sup>1-3&lt;/sup>, but dysfunction due to T cell exhaustion is an important barrier to progress&lt;sup>4-6&lt;/sup>. To investigate the biology of exhaustion in human T cells expressing CAR receptors, we used a model system with a tonically signaling CAR, which induces hallmark features of exhaustion&lt;sup>6&lt;/sup>. Exhaustion was associated with a profound defect in the production of IL-2, along with increased chromatin accessibility of AP-1 transcription factor motifs and overexpression of the bZIP and IRF transcription factors that have been implicated in mediating dysfunction in exhausted T cells&lt;sup>7-10&lt;/sup>. Here we show that CAR T cells engineered to overexpress the canonical AP-1 factor c-Jun have enhanced expansion potential, increased functional capacity, diminished terminal differentiation and improved anti-tumour potency in five different mouse tumour models in vivo. We conclude that a functional deficiency in c-Jun mediates dysfunction in exhausted human T cells, and that engineering CAR T cells to overexpress c-Jun renders them resistant to exhaustion, thereby addressing a major barrier to progress for this emerging class of therapeutic agents.</pubmed_abstract><journal>Nature</journal><pubmed_title>c-Jun overexpression in CAR T cells induces exhaustion resistance.</pubmed_title><pmcid>PMC6944329</pmcid><funding_grant_id>P50 HG007735</funding_grant_id><funding_grant_id>S10 OD018220</funding_grant_id><funding_grant_id>RM1 HG007735</funding_grant_id><pubmed_authors>Majzner R</pubmed_authors><pubmed_authors>Xu P</pubmed_authors><pubmed_authors>Anbunathan H</pubmed_authors><pubmed_authors>Granja J</pubmed_authors><pubmed_authors>Chang HY</pubmed_authors><pubmed_authors>Weber EW</pubmed_authors><pubmed_authors>Good Z</pubmed_authors><pubmed_authors>Lynn RC</pubmed_authors><pubmed_authors>Nagaraja S</pubmed_authors><pubmed_authors>de Bourcy CFA</pubmed_authors><pubmed_authors>Sotillo E</pubmed_authors><pubmed_authors>Gennert D</pubmed_authors><pubmed_authors>Tieu V</pubmed_authors><pubmed_authors>Quake SR</pubmed_authors><pubmed_authors>Mackall CL</pubmed_authors><pubmed_authors>Satpathy AT</pubmed_authors><pubmed_authors>Jones R</pubmed_authors><pubmed_authors>Monje M</pubmed_authors><pubmed_authors>Lattin J</pubmed_authors></additional><is_claimable>false</is_claimable><name>c-Jun overexpression in CAR T cells induces exhaustion resistance.</name><description>Chimeric antigen receptor (CAR) T cells mediate anti-tumour effects in a small subset of patients with cancer&lt;sup>1-3&lt;/sup>, but dysfunction due to T cell exhaustion is an important barrier to progress&lt;sup>4-6&lt;/sup>. To investigate the biology of exhaustion in human T cells expressing CAR receptors, we used a model system with a tonically signaling CAR, which induces hallmark features of exhaustion&lt;sup>6&lt;/sup>. Exhaustion was associated with a profound defect in the production of IL-2, along with increased chromatin accessibility of AP-1 transcription factor motifs and overexpression of the bZIP and IRF transcription factors that have been implicated in mediating dysfunction in exhausted T cells&lt;sup>7-10&lt;/sup>. Here we show that CAR T cells engineered to overexpress the canonical AP-1 factor c-Jun have enhanced expansion potential, increased functional capacity, diminished terminal differentiation and improved anti-tumour potency in five different mouse tumour models in vivo. We conclude that a functional deficiency in c-Jun mediates dysfunction in exhausted human T cells, and that engineering CAR T cells to overexpress c-Jun renders them resistant to exhaustion, thereby addressing a major barrier to progress for this emerging class of therapeutic agents.</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Dec</publication><modification>2024-11-15T22:55:19.206Z</modification><creation>2020-06-07T07:02:03Z</creation></dates><accession>S-EPMC6944329</accession><cross_references><pubmed>31802004</pubmed><doi>10.1038/s41586-019-1805-z</doi></cross_references></HashMap>